Catalog No.
Product Name
Application
Product Information
Citations
-
Leukotriene Receptor Antagonist
ONO4057 is a potent leukotriene B4 receptor antagonist, exhibiting an IC50 of 0.7±0.3 μM. This compound effectively inhibits the activity of leukotriene B4, which plays a crucial role in inflammatory processes. ONO4057 is utilized in research applications focused on inflammation, asthma, and allergy studies, making it valuable for exploring therapeutic strategies in these areas. -
Leukotriene Receptor Antagonist
REV 5901 is a competitive, orally active antagonist of leukotriene receptors, exhibiting a Ki value of 0.7 μM. In addition to its receptor antagonism, REV 5901 also acts as a 5-lipoxygenase inhibitor. This compound is primarily utilized in research related to asthma, where leukotriene release plays a critical role, and has potential applications in the study of colon carcinoma. -
leukotriene Receptor Antagonist
FPL-55712 free base is a leukotriene receptor antagonist that effectively inhibits bronchoconstriction induced by leukotrienes. Additionally, it antagonizes slow reacting substance of anaphylaxis (SRS-A), making it valuable for research focused on respiratory conditions and allergic responses. This compound is instrumental in studies exploring the modulation of leukotriene pathways in inflammatory diseases. -
Leukotriene Synthesis Inhibitor
L-674573 is a quinoline compound that functions as a selective inhibitor of leukotriene synthesis. It effectively inhibits leukotriene production induced by Calcimycin and N-Formyl-Met-Leu-Phe, with IC50 values of 100 nM and 50 nM, respectively. L-674573 specifically targets and inhibits the translocation of 5-lipoxygenase, making it a valuable tool for research into inflammatory processes and leukotriene-related diseases. Its application is particularly relevant in studies aimed at understanding leukotriene signaling pathways and developing anti-inflammatory therapeutics. -
CysLT1 Receptor Antagonist
Pobilukast is a classical antagonist of the CysLT1 receptor, modulating leukotriene-mediated signaling pathways. It demonstrates significant efficacy in inhibiting bronchoconstriction and inflammation associated with asthma. This compound is primarily utilized in research investigating asthma pathophysiology and potential therapeutic interventions targeting leukotriene receptors. -
CysLT1-2R Antagonist
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist, exhibiting IC50 values of 1.2 μM for CysLT1R and 52 μM for CysLT2R. This compound effectively inhibits developmental angiogenesis in the zebrafish eye model, making it a valuable tool for studying ocular neovascular pathologies. Quininib may serve as a complementary agent to existing anti-VEGF biological therapies in research applications focused on angiogenesis and related conditions. -
leukotriene receptor antagonist
Masilukast is a cysteinyl leukotriene D4 (LTD4) receptor antagonist that is administered orally. This compound exhibits significant potential in mitigating the effects of leukotrienes, thus contributing to the management of asthma and related respiratory conditions. It serves as a valuable tool for research into inflammatory pathways and therapeutic interventions targeting asthma. -
CysLT1 Antagonist
Montelukast dicyclohexylamine is a selective and orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1). It demonstrates significant biological activity in inflammatory conditions, making it useful for studying asthma and liver injury. Additionally, Montelukast dicyclohexylamine exhibits antioxidant properties that may mitigate intestinal ischemia-reperfusion injury and reduce cardiac damage. Its capability to decrease eosinophil infiltration in asthmatic airways further highlights its potential in respiratory research, including investigations related to COVID-19. -
Arachidonic Metabolite
Leukotriene F4 (LTF4) is an arachidonic metabolite that belongs to the Cysteinyl Leukotriene (CysTL) family. It is known to induce bronchoconstriction, exhibiting an ED50 of 16 μg/kg, which underscores its role in respiratory pathophysiology. LTF4 is generated from its precursor, Leukotriene E4 (LTE4), through the action of a glutamyl transferase. Its biological activity makes it a relevant target for research on inflammatory and respiratory conditions. -
Leukotriene
Leukotriene B4 dimethyl amide is an immunomodulator that primarily targets leukotriene pathways. It induces contraction in isolated guinea pig lung tissues and promotes migration of human neutrophils. This compound is utilized in research applications focused on understanding inflammatory processes and evaluating potential anti-inflammatory therapies involving leukotriene B4 antagonists. -
Leukotriene Inhibitor
Piriprost potassium is a potent leukotriene synthesis inhibitor. It effectively suppresses the release of leukotrienes and histamine in isolated porcine lung cells, exhibiting an IC50 of 0.11 μM. Additionally, Piriprost potassium enhances alkaline phosphatase (ALP) activity in cultured endometrial stromal cells, making it a useful tool for research in inflammation and reproductive biology. -
Racemate of SC-45694
(Rac)-SC-45694 is a racemic mixture of SC-45694, which acts as a potent leukotriene B4 (LTB4) agonist, promoting neutrophil chemotaxis. It also exhibits antagonist properties that inhibit LTB4-induced neutrophil degranulation. This compound is essential for studies investigating neutrophil function and inflammation-related pathways, making it valuable for research in immunology and related fields. -
Leukotriene Formation Inhibitor
Pirodomast is a potent leukotriene formation inhibitor that targets the release of leukotriene D4 (LTD4) and thromboxane B2 in anaphylactic guinea pig lung tissues. With IC50 values of 3.9 μM for LTD4 and 1.9 μM for thromboxane B2, Pirodomast demonstrates significant inhibitory activity. This compound is valuable for research applications related to asthma and inflammatory responses, providing insights into leukotriene-mediated pathways in respiratory conditions. -
Leukotriene Receptor Antagonist
REV 5901 hydrochloride is a competitive, orally active antagonist of the leukotriene receptor, exhibiting a Ki of 0.7 μM. In addition, it acts as a 5-lipoxygenase inhibitor. This compound is valuable for research into asthma, particularly in studies investigating leukotriene release. Furthermore, REV 5901 hydrochloride may be utilized in the exploration of colon carcinoma mechanisms. -
cPLA2α Inhibitor
ZPL-5212372 is a potent inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 7 nM. This compound efficiently reduces the release of key inflammatory mediators such as prostaglandin D2, cysteinyl leukotrienes, leukotriene B4, and thromboxane A2 from human lung cells. Research indicates that ZPL-5212372 effectively attenuates delayed bronchoconstriction and airway hyperresponsiveness in models of allergic inflammation. Consequently, it serves as a valuable tool for investigating mechanisms and potential therapies for asthma. -
LTB4 Receptor Antagonist
SB-201993 is a selective leukotriene B₄ (LTB4) receptor antagonist with a Ki of 7.6 nM, targeting LTB4 receptors on human inflammatory cells. This compound effectively inhibits calcium mobilization and 5-lipoxygenase activity, leading to significant anti-inflammatory effects. SB-201993 is valuable for research applications focused on inflammatory diseases such as dermatitis and arthritis. -
(5,6)-DiHETE Enantiomers
(5S,6S)-DiHETE is an enantiomer of (5,6)-DiHETE, which primarily targets the peroxisome proliferator-activated receptor (PPAR). This compound exhibits significant biological activity influencing lipid metabolism and inflammatory response pathways. It is utilized in research applications focusing on metabolic disorders and the modulation of inflammatory processes. -
Dual Enkephalinase Inhibitor
PL265 is a dual enkephalinase inhibitor that acts as a prodrug of PL254. It effectively inhibits both neutral endopeptidase (neprilysin) and aminopeptidase N, leading to increased local concentrations of enkephalins like Met-Enkephalin and Leu-Enkephalin. This action subsequently activates μ and δ opioid receptors, resulting in a potent analgesic effect. Additionally, PL265's inhibition of leukotriene A4 hydrolase (LTA4H) may further enhance its anti-inflammatory properties by reducing the production of leukotriene B4 (LTB4). This reagent is particularly valuable in non-addictive chronic pain research. -
LTB4 Antagonist
SC-50605 is a selective leukotriene B4 (LTB4) receptor antagonist that effectively inhibits LTB4-induced chemotaxis. This compound has demonstrated potential in mitigating the effects of inflammatory conditions, including asthma, rheumatoid arthritis, and various skin diseases. Its capacity to block the LTB4 receptor highlights its usefulness in research focused on inflammation-related pathways and therapeutic interventions. -
(5,6)-DiHETEs Enantiomers
(5S,6R)-DiHETE is an enantiomer of the (5,6)-DiHETE family, primarily targeting leukotriene D4 receptors (LTD4). It exhibits significant biological activity by inducing contraction in isolated guinea pig ileum, with an EC50 value of 1.3 μM. This action can be effectively inhibited by LTD4 receptor antagonists, making (5S,6R)-DiHETE an important reagent for research applications focused on leukotriene signaling and gastrointestinal motility studies. -
5-1ipoxygenase Inhibitor/Leukotriene D4 Antagonist
WAY-126299A is an orally active dual inhibitor of 5-lipoxygenase, demonstrating an IC50 of 12.2 μM, and serves as a leukotriene D4 antagonist with a pKB of 6.4. This compound effectively inhibits antigen-induced leukotriene-dependent bronchoconstriction. WAY-126299A is valuable in research related to asthma and other inflammatory conditions where leukotriene signaling plays a critical role. -
Leukotriene Receptor Antagonist
BIIL-260 is a potent leukotriene B(4) receptor antagonist, serving as an effective anti-inflammatory agent. This compound exhibits a reversible and competitive interaction with the LTB4 receptor, demonstrating high affinity with a Ki value of 1.7 nM, particularly on isolated human neutrophil cell membranes. It is suitable for research applications focused on inflammation and leukotriene signaling pathways. -
LTE4 Inhibitor
LY 245769 is a leukotriene E4 (LTE4) inhibitor that functions as an omega-trifluoro analog. It exhibits inhibitory activity by interfering with the omega-oxidation of N-acetyl-LTE4 and leukotriene B4 (LTB4), with an IC50 value of 4 μM. This compound is essential for research on inflammatory processes and bronchoconstriction, contributing to the understanding of leukotriene signaling pathways and their role in respiratory diseases. -
cysLT1 Receptor Antagonist
CP-288886 is a potent cysLT1 receptor antagonist, demonstrating a Ki value of 0.004 μM. It effectively inhibits calcium mobilization in human U937 cells, with an IC50 of 0.0005 μM. This compound exhibits promising anti-asthmatic activity in preclinical models, such as the guinea pig asthma model, making it a valuable tool for researching respiratory diseases, particularly asthma. Its high oral bioavailability further supports its potential for in vivo studies. -
LTD4/LTE4 Antagonist
LY 163443 is a selective antagonist of leukotriene D4 (LTD4) and leukotriene E4 (LTE4), exhibiting significant inhibitory effects on LTD4 and LTE4-mediated biological activities. This compound effectively antagonizes LTD4-induced contractions in guinea pig ileum, trachea, and lung parenchyma, as well as inhibiting tracheal contractions elicited by LTE4. Its application in research includes studying the role of leukotrienes in airway hyperreactivity and potential therapeutic interventions in respiratory conditions. -
Leukotriene D4 Antagonists
L-695499 is a potent, orally active antagonist of the leukotriene D4 receptor. This compound effectively inhibits leukotriene D4-mediated signaling, making it valuable for studies related to inflammation and immunology. Its application extends to research on respiratory diseases and allergic responses, providing insights into therapeutic approaches for managing inflammatory conditions. -
MRP1 Inhibitor
LY329146 is a selective inhibitor of multidrug resistance protein 1 (MRP1). It effectively inhibits the transport of leukotriene C4 (LTC4) with an IC50 of 0.8 μM. This compound is valuable for studies exploring multidrug resistance mechanisms and may have applications in enhancing the efficacy of chemotherapy in resistant cancer cells. -
LTD4/LTE4 Antagonist
MDL 43291 is a competitive antagonist of leukotriene receptors, specifically targeting LTD4 and LTE4 with a pA2 value of 6.7. This compound exhibits selective antagonism, showing no activity against histamine, carbachol, or substance P. MDL 43291 is useful in research related to inflammation and immunology, particularly in studies of asthma and related allergic conditions. -
CysLT Antagonist
ONO 2050297 is a selective antagonist of the cysteinyl leukotriene receptors CysLT1 and CysLT2, demonstrating IC50 values of 17 nM and 0.87 nM, respectively. This compound is valuable for research related to bronchial asthma and other inflammatory conditions where leukotriene signaling plays a critical role. Its high affinity for CysLT receptors makes it an essential tool for investigating therapeutic strategies targeting bronchial hyperreactivity and inflammation. -
Antiallergic Agent
Torososide B is an antiallergic agent that functions by inhibiting the release of leukotrienes from rat peritoneal mast cells, which is induced by calcium ionophore A. This compound exhibits potential for research applications in allergy-related studies and inflammation processes. Its mechanism of action may aid in the investigation of therapeutic strategies for allergic responses. -
Leukotriene Receptor Antagonist
NZ-107 is an orally active leukotriene receptor antagonist that effectively inhibits leukotriene activity, contributing to the modulation of inflammatory responses. This compound is particularly useful in research focused on inflammation and immunology, including studies investigating the mechanisms of anaphylactic reactions. Its ability to antagonize leukotriene receptors makes it a valuable tool for exploring therapeutic strategies for inflammatory diseases. -
LTB4 Antagonist
LTB4 antagonist 1 is an effective leukotriene B4 (LTB4) antagonist with an IC50 value of 288 nM. This carboxamide-acid compound exhibits notable anti-inflammatory properties, making it a valuable tool for research into inflammatory diseases and related pathways. Its ability to inhibit LTB4 can aid in the investigation of inflammatory responses and the development of therapeutic strategies targeting leukotriene signaling. -
LTB4 Antagonist
CP-195543 is a selective, orally active antagonist of the leukotriene B4 (LTB4) receptor, exhibiting IC50 values of 6.8 nM in human neutrophils and 37.0 nM in murine spleen membranes. This compound effectively inhibits CD11b up-regulation and prevents LTB4-mediated neutrophil infiltration. CP-195543 is valuable for research applications focused on inflammatory responses and neutrophil activity. -
CysLT Antagonist
CGP 57698 is a potent antagonist of the cysteinyl leukotriene receptor with a Ki value of 5.7 nM. This compound effectively inhibits bronchoconstriction induced by leukotriene D4 (LTD4), making it valuable for research into asthma and allergic conditions. CGP 57698 serves as a useful tool in studies examining the role of cysteinyl leukotrienes in respiratory diseases. -
LTD4 Antagonist
Bisisorhapontigenin A is a dimer of isorhapontigenin that acts as an antagonist to LTD4. This compound demonstrates significant anti-inflammatory activity, making it valuable for research on inflammatory pathways and conditions. Its mechanism of action may provide insights into therapeutic strategies for diseases associated with LTD4 signaling. -
Leukotriene Receptor Activator
Leukotriene B5 (LTB5) is a leukotriene receptor activator, primarily influencing inflammatory responses. As a metabolite of eicosapentaenoic acid produced via the 5-lipoxygenase (5-LO) pathway, LTB5 is known to increase the contraction of bullfrog lung strips in a concentration-dependent manner. In vivo studies demonstrate that LTB5 (100 nM) can significantly reduce tumor volume in mice with Tm1 murine melanoma cells. Additionally, LTB5 induces chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes at significantly lower levels compared to LTB4, and exhibits reduced platelet aggregation. -
Leukotriene Receptor Inhibitor
12(S)-HEPE is a monohydroxy fatty acid that acts as a leukotriene receptor inhibitor. It is synthesized from eicosapentaenoic acid (EPA) through the action of 12-lipoxygenase (12-LO). In unstimulated neutrophils, 12(S)-HEPE is metabolized to 12(S),20-diHEPE, while stimulated neutrophils generate 5(S),12(S)-HEPE via the 5-lipoxygenase pathway. Its competitive inhibition of arachidonic acid as a substrate for 5-lipoxygenase in leukotriene formation supports its potential anti-inflammatory effects associated with omega-3 fatty acids. -
LTA4H Inhibitor
JNJ-40929837 is a selective and orally active inhibitor of leukotriene A4 hydrolase (LTA4H). This compound effectively inhibits aminopeptidase activity, resulting in the accumulation of Pro-Gly-Pro in serum. JNJ-40929837 is primarily utilized in asthma research to explore its potential therapeutic effects and mechanisms of action related to inflammatory responses. -
Eukotriene-B4 Receptor Antagonist
SC-41930 is an orally active antagonist of the eicosanoid receptor, leukotriene B4 (LTB4). This compound demonstrates significant anti-inflammatory properties, effectively reducing inflammation in the guinea pig model of acetic acid-induced colonic inflammation. SC-41930 is primarily utilized in research focusing on inflammatory diseases and related pathways. -
BLT2 Antagonist
BLT2 antagonist-1 is a selective antagonist of the BLT2 receptor, demonstrated to inhibit the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM, while showing no effect on CHO-BLT1 cells. It also effectively inhibits the binding of leukotriene B4 (LTB4) to the BLT2 receptor, with a Ki value of 132 nM. This compound is valuable for research into inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
Antiallergy Agent
Sch 33303 is an orally active antiallergy agent that inhibits the release of sulfidopeptide leukotrienes, mediating its effects on inflammatory pathways. This compound demonstrates significant potential for research applications related to asthma and other allergic conditions. Its ability to modulate leukotriene signaling positions Sch 33303 as a valuable tool for investigating therapeutic strategies targeting allergic responses. -
Leukotriene
Leukotriene B4-3-aminopropylamide (LTB4-APA) is an immunomodulator that targets the leukotriene pathway. It acts primarily by modulating leukotriene B4 signaling, which plays a crucial role in inflammatory responses. LTB4-APA is valuable for research applications focused on inflammation, immune response modulation, and the investigation of leukotriene-related diseases. -
Leukotriene Antagonist
YM-16638 is a potent orally active leukotriene antagonist targeting leukotrienes C4, D4, and E4. It effectively inhibits their production in guinea pig trachea with IC50 values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. Additionally, YM-16638 demonstrates a dose-dependent inhibitory effect on both early and late antigen-induced respiratory responses in allergic sheep, making it a valuable tool for research in respiratory and allergic conditions. -
LTD4/LTE4 Antagonist
SR2640 is a potent and selective antagonist of leukotriene D4 (LTD4) and leukotriene E4 (LTE4). It effectively inhibits LTD4-induced smooth muscle contractions in the guinea pig ileum and trachea without interfering with histamine-induced contractions. At a concentration of 23 nM, SR2640 prevents the binding of [3H] LTD4 to receptors in guinea pig lung tissue, demonstrating its high affinity. This compound is suitable for research applications related to asthma and bronchoconstriction, as it shifts the dose-response curve for LTD4-induced bronchoconstriction in guinea pigs to the right, correlating with the administered dose of SR2640. -
LTB4 Receptor Antagonist
14,15-Dehydro Leukotriene B4 is a selective antagonist of the leukotriene B4 (LTB4) receptors BLT1 and BLT2, exhibiting a binding affinity with a Ki value of 27 nM for BLT1 and 473 nM for BLT2. This compound effectively inhibits LTB4-induced lysozyme release from rat polymorphonuclear leukocytes, with an IC50 of 1 µM. It is useful in studies focused on inflammation and immune response modulation. -
LTD4 Antagonist
Ro 24-5913 is a potent LTD4 antagonist, exhibiting an IC50 value of 6.4 nM. This compound is primarily utilized in studies focusing on asthma, helping to elucidate the role of leukotrienes in inflammatory pathways. Its effective modulation of LTD4 activity makes it a valuable tool for researchers investigating bronchoconstriction and asthma-related conditions. -
CysLTR1 Antagonist
MEN-91507 is a potent orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLTR1). It effectively inhibits calcium transients induced by Leukotriene D4, exhibiting an insurmountable antagonistic behavior with a pKb of 10.25. MEN-91507 demonstrates significant efficacy in blocking Leukotriene D4-induced bronchoconstriction and microvascular leakage in guinea pig models. This compound is suitable for research applications in the fields of inflammation and immunology. -
Leukotriene Receptor Antagonist
(rac)-ONO 2050297 is a potent leukotriene receptor antagonist targeting both biCysLT1 and CysLT2 receptors, with IC50 values of 17 nM and 0.87 nM, respectively. This benzoxazole derivative is valuable for studies investigating leukotriene-mediated inflammatory responses and potential therapeutic applications in conditions such as asthma and allergic reactions. Its significant antagonistic activity makes it an important tool for researchers studying leukotriene signaling pathways. -
LTD4 Antagonist
Sulukast is a selective antagonist of leukotriene D4 (LTD4), which plays a critical role in bronchoconstriction. By inhibiting LTD4 activity, Sulukast effectively mitigates bronchoconstriction responses associated with this mediator. This compound is valuable in the investigation of asthma and other respiratory conditions influenced by leukotriene signaling pathways. -
BLT1/BLT2 Agonist
12-epi-LTB4 is an agonist for the BLT1 and BLT2 receptors, exhibiting partial agonistic activity against both mBLT1 and mBLT2. This compound has been shown to induce phosphorylation of extracellular signal-regulated kinase in primary mouse keratinocytes, highlighting its significance in signaling pathways. It is useful for research applications focused on investigating inflammatory responses and chemotaxis in cellular models.
